(Q35207615)

7 August 2017

1 reference

title

Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome (English)

1 reference

7 August 2017

1 reference

1 reference

Anne R Miller

1

1 reference

7 August 2017

Garret J Etgen

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Expert Opinion on Investigational Drugs

7 August 2017

published in

1 reference

7 August 2017

volume

12

1 reference

7 August 2017

issue

9

1 reference

7 August 2017

page(s)

1489-1500

1 reference

Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Hemoglobin variants and determination of glycated hemoglobin (HbA1c)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Lipid abnormalities in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Endothelial dysfunction and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Differential expression and activation of a family of murine peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Peroxisome proliferator-activated receptors: from genes to physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Metabolic and additional vascular effects of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Modulators of leukotriene biosynthesis and receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Activation of PPARdelta alters lipid metabolism in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Amelioration by KRP-297, a new thiazolidinedione, of impaired glucose uptake in skeletal muscle from obese insulin-resistant animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Activation of specific RXR heterodimers by an antagonist of RXR homodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.9.1489

10.1517/13543784.12.9.1489

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference